Crosstalk between different family members: IL27 recapitulates IFNγ responses in HCC cells, but is inhibited by IL6-type cytokines

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1864, Issue 3, 2017, Pages 516-526

  Ginolhac, Aurélien ^a   Haan, Serge ^a   Nicot, Nathalie ^c   Behrmann, Iris ^a   Haan, Claude ^a  

^a UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

Hepatocellular carcinoma; IFN ; IL27; IL6 type cytokines; SOCS3; STAT transcription factors

Indexed keywords

ACUTE PHASE PROTEIN; CYTOKINE; FIBRINOGEN; GAMMA INTERFERON; INTERLEUKIN 27; INTERLEUKIN 6; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; GLYCOPROTEIN GP 130; IL27 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INTERLEUKIN 12; INTERLEUKIN DERIVATIVE; SMALL INTERFERING RNA; SOCS3 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPORTER GENE; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LIVER CELL; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CYTOKINE RECEPTOR GP130; FIBRINOGEN; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-6; INTERLEUKINS; MICROARRAY ANALYSIS; PHOSPHORYLATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING 3 PROTEIN;

EID: 85007313308     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2016.12.006     Document Type: Article

References (76)

1. [1] Batten, M., Ghilardi, N., The biology and therapeutic potential of interleukin 27. J. Mol. Med. 85 (2007), 661–672.
2. [2] Kastelein, R.A., Hunter, C.A., Cua, D.J., Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25 (2007), 221–242.
3. [3] Neurath, M.F., Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14 (2014), 329–342.
4. [4] Bosmann, M., Ward, P.A., Modulation of inflammation by interleukin-27. J. Leukoc. Biol. 94 (2013), 1159–1165.
5. [5] Pflanz, S., Timans, J.C., Cheung, J., Rosales, R., Kanzler, H., Gilbert, J., Hibbert, L., Churakova, T., Travis, M., Vaisberg, E., Blumenschein, W.M., Mattson, J.D., Wagner, J.L., To, W., Zurawski, S., McClanahan, T.K., Gorman, D.M., Bazan, J.F., de Waal Malefyt, R., Rennick, D., Kastelein, R.A., IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16 (2002), 779–790.
6. [6] Hibbert, L., Pflanz, S., De Waal Malefyt, R., Kastelein, R.A., IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J. Interf. Cytokine Res. 23 (2003), 513–522.
7. [7] Lucas, S., Ghilardi, N., Li, J., de Sauvage, F.J., IL-27 regulates IL-12 responsiveness of naive CD4 + T cells through Stat1-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 15047–15052.
8. [8] Takeda, A., Hamano, S., Yamanaka, A., Hanada, T., Ishibashi, T., Mak, T.W., Yoshimura, A., Yoshida, H., Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 170 (2003), 4886–4890.
9. [9] Villarino, A., Hibbert, L., Lieberman, L., Wilson, E., Mak, T., Yoshida, H., Kastelein, R.A., Saris, C., Hunter, C.A., The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19 (2003), 645–655.
10. [10] Hamano, S., Himeno, K., Miyazaki, Y., Ishii, K., Yamanaka, A., Takeda, A., Zhang, M., Hisaeda, H., Mak, T.W., Yoshimura, A., Yoshida, H., WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 19 (2003), 657–667.
11. [11] Yoshida, H., Hamano, S., Senaldi, G., Covey, T., Faggioni, R., Mu, S., Xia, M., Wakeham, A.C., Nishina, H., Potter, J., Saris, C.J., Mak, T.W., WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 15 (2001), 569–578.
12. [12] Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Muller-Newen, G., Schaper, F., Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374 (2003), 1–20.
13. [13] Kao, J.T., Lai, H.C., Tsai, S.M., Lin, P.C., Chuang, P.H., Yu, C.J., Cheng, K.S., Su, W.P., Hsu, P.N., Peng, C.Y., Wu, Y.Y., Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naive hepatitis B infection patients. Liver Int. 32 (2012), 928–936.
14. [14] Cao, Y., Zhang, R., Zhang, W., Zhu, C., Yu, Y., Song, Y., Wang, Q., Bai, L., Liu, Y., Wu, K., Wu, J., IL-27, a cytokine, and IFN-lambda1, a type III IFN, are coordinated to regulate virus replication through type I IFN. J. Immunol. 192 (2014), 691–703.
15. [15] Kao, J.T., Feng, C.L., Yu, C.J., Tsai, S.M., Hsu, P.N., Chen, Y.L., Wu, Y.Y., IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study. BMC Gastroenterol., 15, 2015, 50.
16. [16] Zhu, C., Zhang, R., Liu, L., Rasool, S.T., Mu, Y., Sun, W., Hao, Q., Liu, F., Zhu, Y., Wu, J., Hepatitis B virus enhances interleukin-27 expression both in vivo and in vitro. Clin. Immunol. 131 (2009), 92–97.
17. [17] Prieto, J., Melero, I., Sangro, B., Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 12 (2015), 681–700.
18. [18] Bender, H., Wiesinger, M.Y., Nordhoff, C., Schoenherr, C., Haan, C., Ludwig, S., Weiskirchen, R., Kato, N., Heinrich, P.C., Haan, S., Interleukin-27 displays interferon-gamma-like functions in human hepatoma cells and hepatocytes. Hepatology 50 (2009), 585–591.
19. [19] Schoenherr, C., Weiskirchen, R., Haan, S., Interleukin-27 acts on hepatic stellate cells and induces signal transducer and activator of transcription 1-dependent responses. Cell Commun. Signal., 8, 2010, 19.
20. [20] Frank, A.C., Zhang, X., Katsounas, A., Bharucha, J.P., Kottilil, S., Imamichi, T., Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. J. Interf. Cytokine Res. 30 (2010), 427–431.
21. [21] Matta, B.M., Raimondi, G., Rosborough, B.R., Sumpter, T.L., Thomson, A.W., IL-27 production and STAT3-dependent upregulation of B7-H1 mediate immune regulatory functions of liver plasmacytoid dendritic cells. J. Immunol. 188 (2012), 5227–5237.
22. [22] Pot, C., Apetoh, L., Awasthi, A., Kuchroo, V.K., Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27. Semin. Immunol. 23 (2011), 438–445.
23. [23] Vollmer, S., Kappler, V., Kaczor, J., Flügel, D., Rolvering, C., Kato, N., Kietzmann, T., Behrmann, I., Haan, C., Hypoxia-inducible factor 1-alpha; is up-regulated by oncostatin M and participates in oncostatin M signaling. Hepatology 50 (2009), 253–260.
24. [24] Haan, C., Behrmann, I., A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. J. Immunol. Methods 318 (2007), 11–19.
25. [25] Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., Speleman, F., Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol., 3, 2002 (RESEARCH0034).
26. [26] Hampf, M., Gossen, M., A protocol for combined Photinus and Renilla luciferase quantification compatible with protein assays. Anal. Biochem. 356 (2006), 94–99.
27. [27] Eyckerman, S., Broekaert, D., Verhee, A., Vandekerckhove, J., Tavernier, J., Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor. FEBS Lett. 486 (2000), 33–37.
28. [28] Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U., Speed, T.P., Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4 (2003), 249–264.
29. [29] R Core Team, R: a language and environment for statistical computing. https://www.R-project.org, 2016.
30. [30] Smyth, G.K., Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol., 3, 2004, Article3.
31. [31] Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. JRSSB 57 (1995), 289–300.
32. [32] Wickham, H., ggplot2: Elegant Graphics for Data Analysis. 2009, Springer-Verlag, New York.
33. [33] Wickham, H., tidyverse: easily install and load ‘Tidyverse’ packages. R package version 1.0.0. https://CRAN.R-project.org/package=tidyverse, 2016.
34. [34] Robinson, D., broom: convert statistical analysis objects into tidy data frames. R package version 0.4.1. https://CRAN.R-project.org/package=broom, 2016.
35. [35] Richards, C.D., Brown, T.J., Shoyab, M., Baumann, H., Gauldie, J., Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. J. Immunol. 148 (1992), 1731–1736.
36. [36] Schroder, K., Hertzog, P.J., Ravasi, T., Hume, D.A., Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75 (2004), 163–189.
37. [37] Lanford, R.E., Guerra, B., Lee, H., Chavez, D., Brasky, K.M., Bigger, C.B., Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 43 (2006), 961–972.
38. [38] Bode, J.G., Albrecht, U., Häussinger, D., Heinrich, P.C., Schaper, F., Hepatic acute phase proteins – regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur. J. Cell Biol. 91 (2012), 496–505.
39. [39] Castell, J.V., Andus, T., Kunz, D., Heinrich, P.C., Interleukin-6. The major regulator of acute-phase protein synthesis in man and rat. Ann. N. Y. Acad. Sci. 557 (1989), 87–99.
40. [40] Heinrich, P.C., Castell, J.V., Andus, T., Interleukin-6 and the acute phase response. Biochem. J., 265, 1990, 621.
41. [41] Boehm, U., Klamp, T., Groot, M., Howard, J.C., Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15 (1997), 749–795.
42. [42] Costa-Pereira, A.P., Tininini, S., Strobl, B., Alonzi, T., Schlaak, J.F., Is'harc, H., Gesualdo, I., Newman, S.J., Kerr, I.M., Poli, V., Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 8043–8047.
43. [43] Vollmer, S., Haan, C., Behrmann, I., Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cells. Biochem. Pharmacol. 80 (2010), 2066–2073.
44. [44] Schmitz, J., Weissenbach, M., Haan, S., Heinrich, P.C., Schaper, F., SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 275 (2000), 12848–12856.
45. [45] Pflanz, S., Kurth, I., Grotzinger, J., Heinrich, P.C., Muller-Newen, G., Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation. J. Immunol. 165 (2000), 7042–7049.
46. [46] Owaki, T., Asakawa, M., Morishima, N., Mizoguchi, I., Fukai, F., Takeda, K., Mizuguchi, J., Yoshimoto, T., STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production. J. Immunol. 180 (2008), 2903–2911.
47. [47] Gerhartz, C., Heesel, B., Sasse, J., Hemmann, U., Landgraf, C., Schneider-Mergener, J., Horn, F., Heinrich, P.C., Graeve, L., Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J. Biol. Chem. 271 (1996), 12991–12998.
48. [48] Hemmann, U., Gerhartz, C., Heesel, B., Sasse, J., Kurapkat, G., Grotzinger, J., Wollmer, A., Zhong, Z., Darnell, J.E. Jr., Graeve, L., Heinrich, P.C., Horn, F., Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J. Biol. Chem. 271 (1996), 12999–13007.
49. [49] Lehmann, U., Sommer, U., Smyczek, T., Hörtner, M., Frisch, W., Volkmer-Engert, R., Heinrich, P.C., Schaper, F., Haan, S., Determinants governing the potency of STAT3 activation via the individual STAT3-recruiting motifs of gp130. Cell. Signal. 18 (2006), 40–49.
50. [50] Schmitz, J., Dahmen, H., Grimm, C., Gendo, C., Muller-Newen, G., Heinrich, P.C., Schaper, F., The cytoplasmic tyrosine motifs in full-length glycoprotein 130 have different roles in IL-6 signal transduction. J. Immunol. 164 (2000), 848–854.
51. [51] Hirahara, K., Onodera, A., Villarino, A.V., Bonelli, M., Sciume, G., Laurence, A., Sun, H.W., Brooks, S.R., Vahedi, G., Shih, H.Y., Gutierrez-Cruz, G., Iwata, S., Suzuki, R., Mikami, Y., Okamoto, Y., Nakayama, T., Holland, S.M., Hunter, C.A., Kanno, Y., O'Shea, J.J., Asymmetric action of STAT transcription factors drives transcriptional outputs and cytokine specificity. Immunity 42 (2015), 877–889.
52. [52] Huber, M., Steinwald, V., Guralnik, A., Brustle, A., Kleemann, P., Rosenplanter, C., Decker, T., Lohoff, M., IL-27 inhibits the development of regulatory T cells via STAT3. Int. Immunol. 20 (2008), 223–234.
53. [53] Decker, T., Kovarik, P., Meinke, A., GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J. Interf. Cytokine Res. 17 (1997), 121–134.
54. [54] Igarashi, K., Garotta, G., Ozmen, L., Ziemiecki, A., Wilks, A.F., Harpur, A.G., Larner, A.C., Finbloom, D.S., Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor. J. Biol. Chem. 269 (1994), 14333–14336.
55. [55] Greenlund, A.C., Farrar, M.A., Viviano, B.L., Schreiber, R.D., Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J. 13 (1994), 1591–1600.
56. [56] Darnell, J.E. Jr., Kerr, I.M., Stark, G.R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (1994), 1415–1421.
57. [57] Andus, T., Heinrich, P.C., Castell, J.C., Gerok, W., Interleukin-6: a key hormone of the acute phase reaction. Dtsch. Med. Wochenschr. 114 (1989), 1710–1716.
58. [58] Gauldie, J., Richards, C., Harnish, D., Lansdorp, P., Baumann, H., Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci. U. S. A. 84 (1987), 7251–7255.
59. [59] M.R., Icardi, L., Gesellchen, V., Eyckerman, S., De Cauwer, L., Verhelst, J., S.X., Vercauteren, K., Meuleman, P., Leroux-Roels, G., De Bosscher, K., Boutrosf, M., Tavernier, J., The Sin3a repressor complex is a master regulator of STAT transcriptional activity. PNAS 109 (2012), 12058–12063.
60. [60] Haan, S., Keller, J.F., Behrmann, I., Heinrich, P.C., Haan, C., Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation. Cell. Signal. 17 (2005), 1542–1550.
61. [61] Mahboubi, K., Pober, J.S., Activation of signal transducer and activator of transcription 1 (STAT1) is not sufficient for the induction of STAT1-dependent genes in endothelial cells. Comparison of interferon-gamma and oncostatin M. J. Biol. Chem. 277 (2002), 8012–8021.
62. [62] Stross, C., Radtke, S., Clahsen, T., Gerlach, C., Volkmer-Engert, R., Schaper, F., Heinrich, P.C., Hermanns, H.M., Oncostatin M receptor-mediated signal transduction is negatively regulated by SOCS3 through a receptor tyrosine-independent mechanism. J. Biol. Chem. 281 (2006), 8458–8468.
63. [63] Symes, A., Stahl, N., Reeves, S.A., Farruggella, T., Servidei, T., Gearan, T., Yancopoulos, G., Fink, J.S., The protein tyrosine phosphatase SHP-2 negatively regulates ciliary neurotrophic factor induction of gene expression. Curr. Biol. 7 (1997), 697–700.
64. [64] Schaper, F., Gendo, C., Eck, M., Schmitz, J., Grimm, C., Anhuf, D., Kerr, I.M., Heinrich, P.C., Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Biochem. J. 335:Pt 3 (1998), 557–565.
65. [65] Kortylewski, M., Heinrich, P.C., Mackiewicz, A., Klingmüller, U., Schniertzhauer, U., Nakajima, K., Hirano, T., Horn, F., Behrmann, I., Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene 18 (1999), 3742–3753.
66. [66] Miyagi, T., Gil, M.P., Wang, X., Louten, J., Chu, W.M., Biron, C.A., High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells. J. Exp. Med. 204 (2007), 2383–2396.
67. [67] Croker, B.A., Krebs, D.L., Zhang, J.G., Wormald, S., Willson, T.A., Stanley, E.G., Robb, L., Greenhalgh, C.J., Forster, I., Clausen, B.E., Nicola, N.A., Metcalf, D., Hilton, D.J., Roberts, A.W., Alexander, W.S., SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4 (2003), 540–545.
68. [68] Lang, R., Pauleau, A.L., Parganas, E., Takahashi, Y., Mages, J., Ihle, J.N., Rutschman, R., Murray, P.J., SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. 4 (2003), 546–550.
69. [69] Airoldi, I., Tupone, M.G., Esposito, S., Russo, M.V., Barbarito, G., Cipollone, G., Di Carlo, E., Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer. Oncotarget, 6, 2014.
70. [70] Di Carlo, E., Sorrentino, C., Zorzoli, A., Di Meo, S., Tupone, M.G., Ognio, E., Mincione, G., Airoldi, I., The antitumor potential of Interleukin-27 in prostate cancer. Oncotarget 5 (2014), 10332–10341.
71. [71] Hisada, M., Kamiya, S., Fujita, K., Belladonna, M.L., Aoki, T., Koyanagi, Y., Mizuguchi, J., Yoshimoto, T., K.S., Hisada, M., Fujita, K., Belladonna, M.L., Aoki, T., Koyanagi, Y., Mizuguchi, J., Yoshimoto, T., Potent antitumor activity of Interleukin-27. Cancer Res. 64 (2004), 1152–1156.
72. [72] Hu, P., Hu, H.D., Chen, M., Peng, M.L., Tang, L., Tang, K.F., Matsui, M., Belladonna, M.L., Yoshimoto, T., Zhang, D.Z., Xiang, R., Ren, H., Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol. Immunol. 46 (2009), 1654–1662.
73. [73] Murugaiyan, G., Saha, B., IL-27 in tumor immunity and immunotherapy. Trends Mol. Med. 19 (2013), 108–116.
74. [74] Salcedo, R., Stauffer, J.K., Lincoln, E., Back, T.C., Hixon, J.A., Hahn, C., Shafer-Weaver, K., Malyguine, A., Kastelein, R., Wigginton, J.M., IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8 + T cells. J. Immunol. 173 (2004), 7170–7182.
75. [75] Yoshimoto, T., Morishima, N., Mizoguchi, I., Shimizu, M., Nagai, H., Oniki, S., Oka, M., Nishigori, C., Mizuguchi, J., Antiproliferative activity of IL-27 on melanoma. J. Immunol. 180 (2008), 6527–6535.
76. [76] Yoshimoto, T., Chiba, Y., Furusawa, J., Xu, M., Tsunoda, R., Higuchi, K., Mizoguchi, I., Potential clinical application of interleukin-27 as an antitumor agent. Cancer Sci. 106 (2015), 1103–1110.